share_log

Barclays Maintains Overweight on Pacira BioSciences, Lowers Price Target to $38

Benzinga ·  May 8 14:11

Barclays analyst Balaji Prasad maintains Pacira BioSciences (NASDAQ:PCRX) with a Overweight and lowers the price target from $40 to $38.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment